Halozyme Therapeutics Investor Relations Material
Access more data
Revenues under collaborative agreements
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes novel oncology therapies in the United States and internationally. Its human enzymes are based on intellectual property covering the family of human enzymes known as hyaluronidases. The company operates in two segments, Enhanze Technology, and Clinical Development Pipeline Products. The Enhanze Technology segment engages in the research and development of product candidates that use its proprietary technology platform to develop subcutaneous formulations of injectable biologics.
Key slides for Halozyme Therapeutics Inc
Edward "Ted" Decker's Rise to the Top at Home Depot
Explore Ted Decker's transformative impact on Home Depot, including his leadership in retail innovation and strategic vision alongside Craig Menear.
15 Feb 2024
Andy Jassy: Amazon CEO & Pioneer of Cloud Computing
Discover Andy Jassy's remarkable achievements at Amazon, including the creation of Amazon Web Services and his experiences working with Jeff Bezos.
15 Feb 2024
Stripe’s Rumored 2024 IPO
Anticipation grows around Stripe's rumored 2024 IPO, spotlighting its significant influence in the digital payments sector.
9 Feb 2024
🇺🇸 United States